Rabeprazole + Rabeprazole + Rabeprazole + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Dyspepsia
Conditions
Functional Dyspepsia
Trial Timeline
Apr 1, 2010 → Aug 1, 2011
NCT ID
NCT01089543About Rabeprazole + Rabeprazole + Rabeprazole + Placebo
Rabeprazole + Rabeprazole + Rabeprazole + Placebo is a phase 2 stage product being developed by Eisai for Functional Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT01089543. Target conditions include Functional Dyspepsia.
What happened to similar drugs?
0 of 6 similar drugs in Functional Dyspepsia were approved
Approved (0) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01089543 | Phase 2 | Completed |
Competing Products
20 competing products in Functional Dyspepsia